during growth in the presence of strong ␤-lactamase inducers such as cefoxitin, muropeptides are generated and accumulate in the cytoplasm (due to the saturation of AmpD), leading to the AmpR-mediated induction of ampC expression (5, 12, 13, 20, 28) . It is also well known that the mutational inactivation of AmpD leads to the accumulation of muropeptides and highlevel ampC expression, even in the absence of ␤-lactamase inducers, producing the classical constitutively derepressed phenotype of AmpC production (21, 28) . In fact, AmpD inactivation is the most frequently reported mechanism leading to AmpC hyperproduction and ␤-lactam resistance both in Enterobacteriaceae and in P. aeruginosa clinical isolates (1, 15, 19, 31) .
The interplay between resistance mechanisms and bacterial fitness and virulence is a subject of growing interest. The latter are indeed key parameters for predicting the clinical relevance of the resistance mechanisms (effect on virulence), as well as their epidemiological transcendence, dependent on their capacity for persistence in bacterial populations once the selective pressure exerted by the antibiotics disappears (effect on fitness) (25, 26) . Previous work with Salmonella spp., which lack the ampC gene but contain ampD, has revealed two interesting findings in this field: (i) the inactivation of ampD in Salmonella spp. is associated with a significant biological cost and decreased virulence, mediated by the accumulation of muropeptides (7) , and (ii) high-level expression of ampC from a foreign plasmid also leads to significant decreases in virulence and in vivo fitness (27) .
Interestingly, in contrast to the classical fully derepressed phenotypes observed in Enterobacteriaceae, the inactivation of AmpD in P. aeruginosa has been shown to lead to a partially derepressed phenotype, characterized by a moderately high level basal ampC expression that is still further inducible in the presence of inducers (19) . Recent studies have shown that the partial derepression of the P. aeruginosa ampD mutant is due to the presence of two additional ampD genes, designated ampDh2 and ampDh3, in this species (16) . Furthermore, the sequential inactivation of the three ampD genes has been shown to lead to a stepwise upregulation of ampC expression, reaching full derepression with very high level basal ampC expression (more than 1,000-fold compared to wild-type expression) in the triple mutant (16) . Certainly, this is an interesting and complex system that needs to be studied further, since it is the first instance in which the expression of a chromosomally encoded resistance mechanism can be sequentially amplified through multiple steps of derepression. In this work, we explored the biological role of P. aeruginosa AmpD multiplicity in providing a mechanism for the sequential amplification of an antibiotic resistance gene and in avoiding the biological cost of the first-step resistant mutant (single ampD mutant).
MATERIALS AND METHODS
Bacterial strains, plasmids, and antibiotics. Laboratory strains and plasmids used or constructed in this work are listed in (16) . These mutants had been constructed by following the procedure described by Quénée et al. (29) for gene deletion and antibiotic resistance marker recycling in P. aeruginosa using the cre-lox system. By this procedure, two isogenic pairs of strains were obtained for each of the knockout mutants: one with and one without the (gentamicin) resistance marker (16) . The antibiotics used (gentamicin, ampicillin, carbenillicin, and tetracycline) were purchased from Sigma-Aldrich.
Construction of ampC knockout mutants. The procedure for gene deletion and antibiotic resistance marker recycling in P. aeruginosa using the cre-lox system, described above, was used for the construction of the ampC knockout mutants of PAO1 (PA⌬C) and of the triple ampD mutant (PA⌬DDh2Dh3C). Briefly, upstream and downstream PCR products (Table 2) of ampC were digested with either BamHI or EcoRI and HindIII and then cloned by three-way ligation into pEX100Tlink deleted for the HindIII site and opened by EcoRI and BamHI to produce plasmid pEXAC, which was transformed into Escherichia coli strain XL1-Blue. Transformants were selected on LB agar (LBA) plates with 30 g/ml ampicillin. The lox-flanked gentamicin resistance cassette (aac1) obtained by HindIII restriction of plasmid pUCGmlox was cloned into the single site for this enzyme formed by ligation between the two flanking fragments, producing plasmid pEXACGm, which was transformed into E. coli XL1-Blue. Transformants were selected on LBA plates with 30 g/ml ampicillin and 5 g/ml gentamicin. These plasmids were then transformed into the E. coli helper strain S17-1. Plasmid pEXACGm was transferred from E. coli S17-1 to PAO1 or PA⌬DDh2Dh3 to produce the PA⌬CGm or PA⌬DDh2Dh3CGm mutant, respectively, after selection for double recombinants using LBA plates with 5% sucrose and 30 g/ml gentamicin. Double recombinants were checked first by screening for susceptibility to carbenillicin (200 g/ml) and afterwards by PCR amplification using primers AmpC-F-ERI and AmpC-R-BHI (Table 2 ). For the recycling of the gentamicin resistance cassettes (to yield the PA⌬C and PA⌬DDh2Dh3C mutants), plasmid pCM157 was electroporated into the differ- (30) . Transformants were selected on LBA plates with 250 g/ml tetracycline. One transformant for each mutant was grown overnight in LB broth with 250 g/ml tetracycline in order to allow the expression of the cre recombinase. Plasmid pCM157 was then cured from the strains by three successive passages in LB broth. Selected colonies were then screened for susceptibility to tetracycline (250 g/ml) and gentamicin (30 g/ml) and were checked by PCR amplification and DNA sequencing.
In vitro competition experiments. In vitro competition experiments between each of the ampD mutants (harboring the gentamicin resistance marker) described above and PAO1 were performed. Additionally, competition experiments were performed between strains PA⌬DDh2Dh3CGm and PA⌬DDh2Dh3 (triple ampD mutants with and without ampC inactivated) and between strains PA⌬CGm and PAO1 as controls. Exponentially growing cells of the corresponding mutant and wild-type strains in LB broth were mixed in a 1:1 ratio and diluted in 0.9% saline solution. Approximately 10 3 cells from each of the mixtures were inoculated into eight 10-ml LB broth flasks and grown at 37°C and 180 rpm for 16 to 18 h, corresponding to approximately 20 generations. Serial 10-fold dilutions were plated in duplicate onto LBA alone and LBA with 15 g/ml of gentamicin (LBA-Gm) in order to determine the total CFU and the CFU of the mutant, respectively, after overnight incubation at 37°C. Alternatively, when the difference in the number of colonies between the LBA and LBA-Gm plates was low (less than twofold), 100 randomly selected colonies from the LBA plates were replicated in LBA-Gm plates; mutant and wild-type colonies were recognized by the presence or absence of growth in these plates after overnight incubation. The competition index (CI) was defined as the mutant/wild-type ratio. CI values were calculated for each of the eight independent competitions, and the median values were recorded. Statistical analysis of the distribution of the CI values was performed using the Mann-Whitney U test. P values of Ͻ0.05 were considered to be statistically significant. During the standardization of the procedure, competition experiments between strains PA⌬DGm (PAO1 ampD mutant harboring the Gm resistance cassette) and PA⌬D (PAO1 ampD mutant not harboring the Gm resistance cassette) were performed; the CI values obtained (median CI, 0.95) ruled out any significant effect of the gentamicin resistance cassette on bacterial fitness. To assess the growth rates under noncompetitive conditions, the doubling times of exponentially growing cells in LB broth at 37°C and 180 rpm were determined by plating serial 10-fold dilutions on LBA at 1-h intervals. Three independent experiments were performed for each of the mutants, and the results were compared with those for PAO1 using Student's t test.
Virulence and fitness in the mouse model of systemic infection. To assess the effect on virulence, approximately 5 ϫ 10 6 exponentially growing cells of PAO1, PA⌬D, PA⌬Dh2, PA⌬Dh3, PA⌬DDh2, PA⌬DDh3, PA⌬DDh2Dh3, or PA⌬DDh2Dh3C were inoculated intraperitoneally into groups of 16 ICR(CD1) mice (Harlan Interfauna Ibérica, Barcelona, Spain) weighing 20 to 25 g, and mortality was monitored daily for 7 days. In vivo fitness was assessed by competition experiments in the mouse model of systemic infection. For this purpose, 1:1 mixtures of each of the mutant-wild-type pairs containing a total of approximately 5 ϫ 10 6 exponentially growing cells were inoculated intraperitoneally into eight 20-to 25-g ICR(CD1) mice. When indicated (see Results), competition experiments were also performed using a starting mutant/wild-type ratio of 10:1 or 10:10. Mice were sacrificed 24 h after inoculation, and their spleens were aseptically extracted and homogenized in 2 ml of 0.9% saline solution using the Ultra-Turrax T-25 disperser (IKA, Staufen, Germany). The number of CFU of each strain and the CI values were determined as described for in vitro competition experiments.
Sequencing of the ampDh2 and ampDh3 genes in AmpC-hyperproducing clinical P. aeruginosa isolates. A collection of 10 previously characterized pairs of isogenic clinical strains was further studied (15) . Each pair of strains consisted of an isolate showing wild-type AmpC production and a subsequent isogenic isolate showing AmpC hyperproduction, obtained after treatment with ␤-lactams (15) . Each pair of clinical strains was recovered from a different patient, and each pair belonged to a different clone (15) . Six of the 10 AmpC-hyperproducing isolates had previously been shown to contain ampD-inactivating mutations (15) . In the present work, we explored whether these isolates may additionally contain inactivating mutations in ampDh2 and/or ampDh3. For this purpose, these genes were amplified by PCR using primer pairs ADh2-FBHI-ADh2-RBHI and ADh3-FBHI-ADh3-RBHI, described previously (16) , and were fully sequenced for the 10 pairs of isolates. Sequencing reactions were performed with the BigDye Terminator kit (Perkin-Elmer Applied Biosystems, Foster City, CA), and sequences were analyzed on an ABI Prism 3100 DNA sequencer (PerkinElmer Applied Biosystems). The resulting sequences were then compared (http: //blast.ncbi.nlm.nih.gov/Blast.cgi) with those previously reported for the wildtype PAO1 strain (16) .
RESULTS
In vitro competition experiments. Figure 1 shows the CI values obtained for each of the in vitro competition experiments, and Table 3 summarizes the data on ampC expression and ceftazidime susceptibility, obtained as part of a previous work (16) , as well as presenting the doubling time of each of the mutants studied. None of the single or double ampD mutants showed a significant modification of the growth rate; doubling times ranged from 28.3 to 37.6 min (30.0 min for PAO1) (Table 3) . On the other hand, the triple ampD mutant (PA⌬DDh2Dh3), in which AmpC was fully derepressed, showed a clearly reduced growth rate, with a doubling time of 78.2 min (P ϭ 0.01 for comparison to PAO1) ( Table 3) . Con- sistent with the growth rates, the results for the PA⌬DGm-PAO1 competition (median CI, 0.78; P ϭ 0.8) showed that the inactivation of ampD in PAO1 was not associated with a significant fitness cost in vitro (Fig. 1) . The ampD ampDh2 double mutant was not associated with a significant cost, either (median CI for the PA⌬DDh2Gm-PAO1 competition, 0.83), and the ampD ampDh3 double mutant showed only a modest (though statistically significant [P ϭ 0.0003]) reduction in fitness (median CI for the PA⌬DDh3Gm-PAO1 competition, 0.61) (Fig. 1) . On the other hand, the simultaneous inactivation of the three ampD genes resulted in a marked decrease in fitness, as shown by the median CI of 0.25 for the PA⌬DDh2Dh3Gm-PAO1 competition (P Ͻ 0.0001). Nevertheless, the documented doubling time for the triple ampD mutant (double that for wild-type PAO1) should predict a much lower CI (approximately 0.001) in the competition experiments. The higher-than-expected CI might be explained by the fact that the differences in the growth rate between the triple ampD mutant and PAO1 were not that sharp in late-log phase (data not shown).
To explore whether ampC derepression was responsible for the reduced fitness of the triple ampD mutant, the corresponding ampC knockout mutants were constructed. As shown in Fig. 1 , ampC derepression itself was found to be the main factor responsible for the in vitro cost documented, since inactivation of ampC restored the fitness of the triple ampD mutant to wild-type levels (median CI for the PA⌬DDh2Dh3CGm-PAO1 competition, 0.80; P ϭ 0.9). Similarly, the triple ampD mutant with ampC inactivated clearly outcompeted the triple ampD mutant (median CI for the PA⌬DDh2Dh3CGm-PA⌬DDh2Dh3 competition, 4.28; P Ͻ 0.0001) (Fig. 1) . Furthermore, the inactivation of ampC in the triple ampD mutant restored its growth rate to wildtype levels (doubling time, 37.6 min) ( Table 3) . Control competition experiments between the PAO1 ampC mutant (PA⌬C) and PAO1 ruled out any significant effect of ampC inactivation on fitness in the wild-type strain (median CI, 0.95) (Fig. 1) . Similarly, the growth rate of PA⌬C was not modified from that of PAO1 (Table 3) . Overall, the results of the in vitro experiments show that P. aeruginosa can tolerate moderate overexpression (up to 2 log units) of AmpC without a significant effect on growth but that, in contrast, when the level of AmpC expression reaches a certain threshold (around 3 log units), fitness is significantly reduced.
Fitness and virulence in the mouse model of systemic infection. Results for the in vivo competition experiments in the mouse model of systemic infection are presented in Table 4 . As shown, all the single ampD mutants retained full in vivo fitness relative to that of the wild-type strain, since none of them was outcompeted by PAO1 (median CI values, 0.94 to 1.02). On the other hand, the ampD ampDh2 double mutant was associated with a significant biological cost (median CI, 0.23; P Ͻ 0.001), and the ampD ampDh3 double mutant lost its biological competitiveness completely (median CI, Ͻ0.01). Accordingly, the ampD ampDh2 ampDh3 triple mutant was completely outcompeted by PAO1, even when the competition experiments were performed with an initial 10:1 mutant/wild-type ratio (Table 4) . Furthermore, in contrast to the results of in vitro competitions, ampC inactivation did not restore the in vivo fitness of the triple mutant at all (median CI for the PA⌬DDh2Dh3CGm-PAO1 competition, Ͻ0.01), showing that AmpC derepression is not the main driver of the marked biological cost determined by the sequential inactivation of the ampD genes. Nevertheless, ampC derepression itself caused a significant reduction of in vivo fitness, since the triple mutant with ampC inactivated clearly outcompeted the triple mutant (median CI for the PA⌬DDh2Dh3CGm-PA⌬DDh2Dh3 competition, 12.5).
To assess the effect on virulence of the inactivation of the ampD genes, the mortality rates for groups of 16 mice inoculated with each of the strains studied were monitored daily for 7 days. As shown in Fig. 2 , the inactivation of ampD or ampDh2 did not modify the mouse survival curve at all. On the other hand, remarkably, the inactivation of ampDh3 dramatically reduced mortality to 0% after 7 days, suggesting that this gene plays a major role in virulence. Accordingly, no mortality was observed for the ampD ampDh3 double mutant (Fig. 2) , the triple mutant, or the triple mutant with ampC inactivated (data not shown). Finally, the ampD ampDh2 double mutant produced significantly (P Ͻ 0.001) lower mortality than either the ampD or the ampDh2 single mutant (Fig. 2) . a Relative amount of ampC mRNA expression compared to basal expression in PAO1. Induction experiments were carried out with 50 g/ml cefoxitin. NC, no change in ampC expression compared to PAO1 basal expression; NA, not applicable.
b ampC expression and ceftazidime MIC data for PAO1, PA⌬D, PA⌬Dh2, PA⌬Dh3, PA⌬DDh2, PA⌬DDh3, and PA⌬DDh2Dh3 were obtained from reference 16 .
c For exponential growth in LB broth at 37°C and 180 rpm. *, P ϭ 0.01 for comparison to PAO1. 
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Sequencing of the ampDh2 and ampDh3 genes in AmpChyperproducing P. aeruginosa clinical isolates. The natural occurrence of P. aeruginosa double or triple ampD mutants was investigated in a collection of 10 previously characterized pairs of isogenic clinical strains (15) . Each pair of strains consisted of an isolate showing wild-type AmpC production and a subsequent isogenic isolate showing AmpC hyperproduction, obtained after treatment with ␤-lactams (15) . Each pair of clinical strains was recovered from a different patient, and each belonged to a different clone (15) . Six of the 10 AmpC-hyperproducing isolates had previously been found to contain ampD-inactivating mutations, whereas the mechanisms leading to AmpC hyperproduction were unknown for the other 4 strains (15) ( Table 5 ). The results of the sequencing of the ampDh2 and ampDh3 genes are shown in Table 5 . Although some of the strains showed differences of one amino acid from the sequence of PAO1 (Table 5) , these substitutions were always present in the wild-type isogenic isolates, suggesting that they are natural polymorphisms rather than inactivating mutations and therefore that double and triple ampD mutants are not frequent in the clinical setting.
DISCUSSION
The development of resistance by Pseudomonas aeruginosa during antimicrobial therapy, mediated by the selection of mutations in chromosomal genes, is a frequent problem with major clinical consequences (3, 6, 24) . Particularly noteworthy among the mutation-mediated resistance mechanisms are those leading to the hyperproduction of the chromosomal cephalosporinase AmpC, which confers resistance to all the antipseudomonal penicillins and cephalosporins (23) . Indeed, failure of treatment with ␤-lactams due to the selection of AmpC-hyperproducing mutants is a frequent outcome of P. aeruginosa infections (8, 15, 22) . Furthermore, AmpC hyperproduction is one of the most prevalent resistance mechanisms documented among clinical P. aeruginosa strains, even among those isolated from patients with severe bloodstream infections (10) , showing that the pathogenic capacity is not at all impaired. Along the same lines, AmpC hyperproduction is a frequent contributor to multidrug resistance in P. aeruginosa (9) and, combined with other mutational resistance mechanisms, is responsible for the origination of panresistant epidemic clones (4).
In contrast to the classical phenotype of full AmpC derepression generally reported for Enterobacteriaceae, P. aeruginosa clinical isolates most frequently show partially derepressed phenotypes (23) . Indeed, the inactivation of AmpD in this species leads to a moderately high level basal ampC expression that is still further inducible in the presence of inducers, due to the production of two additional N-acetyl-anhydromuramyl-L-alanine amidases, AmpDh2 and AmpDh3 (16, 19) . Homology searches using the available databases with the complete genome sequences of E. coli and other members of the Enterobacteriaceae revealed the presence of one, and only one, ampD homologue in addition to the regular ampD gene (16) . This additional N-acetyl-anhydromuramyl-L-alanine amidase has recently been fully characterized in E. coli, where it has been designated AmiD (32) . AmiD was shown to contain the signal sequence of outer membrane lipoproteins, and indeed its location in the outer membrane was demonstrated, in contrast to the cytoplasmic location of AmpD (32) . P. aeruginosa AmpDh2 has the same signal sequence of outer membrane lipoproteins, suggesting that this amidase is the AmiD homologue. Therefore, AmpDh3 appears to be the extra amidase of P. aeruginosa. Indeed, AmpDh3 was previously shown to contribute much more than AmpDh2 to ampC repression in the ampD mutant background, thus playing a more relevant role in the characteristic partially derepressed phenotype of P. aeruginosa (16) .
In this work we show that AmpD multiplicity in P. aeruginosa plays a major role in coupling the acquisition of antibiotic resistance with the maintenance of biological competitiveness and virulence. While full AmpC derepression is shown to impose a marked fitness cost both in vitro and in vivo, partial derepression, mediated by ampD inactivation in the presence of ampDh2 and particularly ampDh3, does not modify biological competitiveness. Furthermore, independently of ampC expression, the inactivation of two or all three ampD genes im- Nevertheless, remarkably, in contrast to the inactivation of ampD or ampDh2, ampDh3 inactivation dramatically reduced the mortality of mice, suggesting that this gene plays a major role in virulence. The reason for the differential effect on virulence of ampDh3 inactivation, compared to ampD or ampDh2 inactivation, still remains to be elucidated. One of the possibilities that should be further explored is a potential role in cell wall degradation for the establishment of gaps in peptidoglycan, which are required for the assembly of type III and IV secretion systems (17) . Previous studies have shown that AmpD is required for the recycling of peptidoglycan catabolism products and that its inactivation leads to the accumulation of muropeptides (28) . Furthermore, a recent work showed that the accumulation of muropeptides, determined by ampD inactivation, causes a marked reduction of in vivo fitness and virulence in Salmonella enterica (7) . Indeed, this marked difference in the biological consequences of ampD inactivation between Salmonella enterica and P. aeruginosa is expected to be dependent on the presence of AmpDh3 in the latter species; the single ampD mutant of Salmonella enterica should be equivalent to the P. aeruginosa ampD ampDh3 double mutant, which is completely impaired in fitness and virulence.
While full ampC derepression in P. aeruginosa, mediated by the sequential inactivation of the three ampD genes, confers high-level resistance to antipseudomonal ␤-lactams and partial derepression confers only moderate resistance, our results predict that the former phenotype should be very uncommon in the clinical setting, due to its high biological cost. Consistent with this hypothesis, none of the 10 natural AmpC-hyperproducing mutants characterized in this work seemed to contain inactivating mutations in ampDh2 or ampDh3. Nevertheless, previous work shows that there are yet unidentified pathways, independent of the ampD genes, leading to high-level ampC expression, whose effects on fitness and virulence remain to be explored (15, 19) .
In summary, we show that P. aeruginosa AmpD multiplicity plays a major role in coupling the acquisition of antibiotic resistance with the maintenance of biological competitiveness and virulence. Due to the presence of ampDh2 and ampDh3, partial ampC derepression mediated by ampD inactivation confers a biologically efficient resistance mechanism on P. aeruginosa.
